Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry
Condition(s):Metastatic Differentiated Thyroid CancerLast Updated:March 29, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Differentiated Thyroid CancerLast Updated:March 29, 2022Recruiting
Condition(s):Differentiated Thyroid Cancer; Thyroid Cancer, NonmedullaryLast Updated:February 26, 2024Active, not recruiting
Condition(s):Recurrent Thyroid CancerLast Updated:May 31, 2023Recruiting
Condition(s):Papillary Thyroid CancerLast Updated:February 15, 2024Not yet recruiting
Condition(s):Thyroid Cancer, AnaplasticLast Updated:June 21, 2018Unknown status
Condition(s):Differentiated Thyroid CancerLast Updated:June 19, 2017Completed
Condition(s):Differentiated Thyroid CancerLast Updated:August 28, 2019Terminated
Condition(s):Thyroid Carcinoma; Thyroid Cancer; Thyroid Cancer, Follicular; Thyroid Cancer (Follicular Cell); Thyroid Cancer, Papillary; BRAF V600E Mutation PositiveLast Updated:February 28, 2024Completed
Condition(s):Thyroid Cancer; RecurrenceLast Updated:October 13, 2023Recruiting
Condition(s):Thyroid CancerLast Updated:August 15, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.